Caliway Biopharmaceuticals Co., Ltd. - Laporan Laba Rugi (TTM)

Caliway Biopharmaceuticals Co., Ltd.
TW ˙ TWSE
NT$ 255.00 ↓ -2.50 (-0.97%)
2025-09-09
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Caliway Biopharmaceuticals Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
12-31
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 10 12 6 0 6 13 16 28 30 39 39 36 50 44 40 45
Change (%) 19.22 -49.71 -98.84 8,852.78 98.88 28.60 69.70 8.65 28.07 0.68 -9.39 40.72 -11.09 -8.93 10.78
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 4 3 2 0 2 3 4 8 9 11 12 10 15 14 12 14
Change (%) -15.48 -49.50 -98.02 5,132.26 98.09 37.77 85.23 8.57 28.77 0.74 -10.34 47.86 -10.69 -9.61 11.59
% of Revenue 35.51 25.17 25.28 43.06 25.16 25.06 26.85 29.30 29.28 29.44 29.46 29.15 30.63 30.77 30.54 30.76
Gross Operating Profit 7 9 5 0 5 10 12 20 21 27 28 25 35 31 28 31
Change (%) 38.32 -49.78 -99.12 11,665.85 99.15 25.54 64.01 8.69 27.77 0.65 -8.99 37.78 -11.27 -8.62 10.43
% of Revenue 64.49 74.83 74.72 56.94 74.84 74.94 73.15 70.70 70.72 70.56 70.54 70.85 69.37 69.23 69.46 69.24
SG&A 23 59 61 63 49 34 34 32 34 37 39 56 83 98 113 162
Change (%) 154.79 2.92 2.84 -22.77 -29.48 0.53 -6.40 4.68 9.63 4.93 44.83 47.08 18.42 15.54 43.39
% of Revenue 225.05 480.99 984.33 87,244.44 752.64 266.88 208.62 115.06 110.86 94.90 98.91 158.09 165.24 220.07 279.19 361.36
R&D 89 181 198 215 255 295 332 455 486 504 646 644 653 650 619 536
Change (%) 102.98 9.54 8.71 18.58 15.67 12.43 37.30 6.77 3.66 28.17 -0.32 1.36 -0.39 -4.82 -13.42
% of Revenue 859.74 1,463.79 3,188.35 298,734.72 3,956.76 2,301.22 2,011.80 1,627.63 1,599.40 1,294.54 1,648.02 1,813.01 1,305.87 1,463.11 1,529.13 1,195.01
OpEx 116 243 261 278 305 332 371 496 529 552 696 710 751 762 744 712
Change (%) 109.63 7.17 6.69 9.81 8.93 11.45 33.81 6.66 4.46 26.04 2.03 5.65 1.47 -2.29 -4.38
% of Revenue 1,120.30 1,969.95 4,197.95 386,022.22 4,734.56 2,593.17 2,247.27 1,772.00 1,739.54 1,418.88 1,776.39 2,000.25 1,501.74 1,713.95 1,838.86 1,587.13
Operating Income -106 -231 -254 -278 -299 -320 -354 -468 -498 -513 -657 -675 -701 -717 -704 -667
Change (%) 118.50 10.21 9.27 7.51 6.99 10.76 32.14 6.54 3.02 27.97 2.71 3.80 2.37 -1.88 -5.25
% of Revenue -1,020.30 -1,869.95 -4,097.95 -385,922.22 -4,634.56 -2,493.17 -2,147.27 -1,672.00 -1,639.54 -1,318.88 -1,676.39 -1,900.25 -1,401.74 -1,613.95 -1,738.86 -1,487.13
Interest Expense -5 -3 -2 -1 -1 -1 -1 -1 -1 -0 -0 -0 -0 -0 -0 -0
Change (%) -35.62 -24.97 -33.29 -27.01 -37.01 -5.76 -7.70 -6.28 -8.54 -8.43 -8.99 -9.88 -11.23 -12.65 -15.52
% of Revenue -43.57 -23.53 -35.10 -2,018.06 -16.45 -5.21 -3.82 -2.08 -1.79 -1.28 -1.16 -1.17 -0.75 -0.75 -0.72 -0.55
Net Income -98 -224 -244 -263 -275 -286 -322 -429 -454 -488 -612 -622 -651 -589 -546 -618
Change (%) 127.74 8.63 7.95 4.40 4.21 12.60 33.18 5.83 7.56 25.25 1.74 4.59 -9.55 -7.29 13.22
% of Revenue -951.56 -1,817.76 -3,926.50 -365,311.11 -4,259.84 -2,232.10 -1,954.26 -1,533.64 -1,493.83 -1,254.64 -1,560.87 -1,752.59 -1,302.60 -1,325.18 -1,349.02 -1,378.67

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista